- Home
- ATXS vs ORIC Comparison
ATXS vs ORIC Comparison
Compare ATXS & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- ORIC
- Stock Information
- Founded
- ATXS 2008
- ORIC 2014
- Country
- ATXS United States
- ORIC United States
- Employees
- ATXS N/A
- ORIC N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- ATXS Health Care
- ORIC Health Care
- Exchange
- ATXS Nasdaq
- ORIC Nasdaq
- Market Cap
- ATXS 584.1M
- ORIC 633.7M
- IPO Year
- ATXS 2015
- ORIC 2020
- Fundamental
- Price
- ATXS $9.55
- ORIC $8.25
- Analyst Decision
- ATXS Strong Buy
- ORIC Strong Buy
- Analyst Count
- ATXS 5
- ORIC 9
- Target Price
- ATXS $28.00
- ORIC $18.75
- AVG Volume (30 Days)
- ATXS 340.4K
- ORIC 294.2K
- Earning Date
- ATXS 11-13-2024
- ORIC 11-12-2024
- Dividend Yield
- ATXS N/A
- ORIC N/A
- EPS Growth
- ATXS N/A
- ORIC N/A
- EPS
- ATXS N/A
- ORIC N/A
- Revenue
- ATXS N/A
- ORIC N/A
- Revenue This Year
- ATXS N/A
- ORIC N/A
- Revenue Next Year
- ATXS N/A
- ORIC N/A
- P/E Ratio
- ATXS N/A
- ORIC N/A
- Revenue Growth
- ATXS N/A
- ORIC N/A
- 52 Week Low
- ATXS $5.88
- ORIC $6.33
- 52 Week High
- ATXS $16.90
- ORIC $16.65
- Technical
- Relative Strength Index (RSI)
- ATXS 41.21
- ORIC 36.28
- Support Level
- ATXS $9.40
- ORIC $8.07
- Resistance Level
- ATXS $9.99
- ORIC $8.62
- Average True Range (ATR)
- ATXS 0.58
- ORIC 0.49
- MACD
- ATXS -0.01
- ORIC -0.17
- Stochastic Oscillator
- ATXS 9.32
- ORIC 14.29
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.